Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on Thursday, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sunil Healthcare Ltd's Board met on May 29, 2025 and approved the audited standalone and consolidated financial results for Q4 and full year ended March 31, 2025. Statutory auditors Singhi & Co. issued an unmodified (clean) opinion on the results. Standalone revenue from operations for FY25 stood at around Rs. 8,436.68 lakhs with a net profit of approximately Rs. 1,025.44 lakhs. The Board decided NOT to recommend any dividend for FY 2024-25. The Board also appointed M/s. ATCS & Associates as Secretarial Auditor for five years (FY 2025-26 to FY 2029-30), subject to shareholder approval, and M/s. Agrawal S. Lal & Co. as Internal Auditors for FY 2025-26. Two foreign subsidiaries (Mexico and North America) contributed marginal revenue but incurred losses, which were consolidated.
Shareholders will see no dividend income for FY25, which may weigh on the stock. However, a clean audit opinion and continued profitability signal stable operations. The loss-making foreign subsidiaries remain a concern but are not material to the group overall.